Henan Lingrui Pharmaceutical Co Ltd (600285) — Cash Flow-to-Debt Ratio
Henan Lingrui Pharmaceutical Co Ltd (600285) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of CN¥140.12 Million could theoretically repay 0% of its total liabilities (CN¥2.47 Billion) in one year. See how much free cash does Henan Lingrui Pharmaceutical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Henan Lingrui Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Henan Lingrui Pharmaceutical Co Ltd across 27 annual periods. Also explore 600285 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
Year-by-year debt coverage analysis for Henan Lingrui Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see 600285 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | CN¥553.88 Million | CN¥2.20 Billion | ▼ -44.3% |
| 2024 | 0.45x | CN¥875.86 Million | CN¥1.94 Billion | ▲ +9.7% |
| 2023 | 0.41x | CN¥813.43 Million | CN¥1.97 Billion | ▼ -11.8% |
| 2022 | 0.47x | CN¥834.91 Million | CN¥1.79 Billion | ▼ -16.7% |
| 2021 | 0.56x | CN¥845.69 Million | CN¥1.51 Billion | ▲ +41.5% |
| 2020 | 0.40x | CN¥450.53 Million | CN¥1.14 Billion | ▼ -3.5% |
| 2019 | 0.41x | CN¥450.15 Million | CN¥1.10 Billion | ▼ -4.3% |
| 2018 | 0.43x | CN¥436.25 Million | CN¥1.02 Billion | ▲ +347.3% |
| 2017 | 0.10x | CN¥105.97 Million | CN¥1.10 Billion | ▲ +32.0% |
| 2016 | 0.07x | CN¥63.26 Million | CN¥869.35 Million | ▼ -54.3% |
| 2015 | 0.16x | CN¥156.82 Million | CN¥984.58 Million | ▲ +17.1% |
| 2014 | 0.14x | CN¥124.32 Million | CN¥913.70 Million | ▼ -29.1% |
| 2013 | 0.19x | CN¥127.27 Million | CN¥663.24 Million | ▲ +642.7% |
| 2012 | 0.03x | CN¥15.43 Million | CN¥597.36 Million | ▼ -66.6% |
| 2011 | 0.08x | CN¥40.49 Million | CN¥524.02 Million | ▲ +1056.7% |
| 2010 | -0.01x | CN¥-3.95 Million | CN¥489.25 Million | ▼ -102.3% |
| 2009 | 0.35x | CN¥132.61 Million | CN¥378.52 Million | ▲ +235.4% |
| 2008 | 0.10x | CN¥43.72 Million | CN¥418.55 Million | ▲ +137.4% |
| 2007 | 0.04x | CN¥15.99 Million | CN¥363.31 Million | ▼ -35.6% |
| 2006 | 0.07x | CN¥26.76 Million | CN¥392.03 Million | ▼ -19.9% |
| 2005 | 0.09x | CN¥33.43 Million | CN¥392.44 Million | ▼ -13.8% |
| 2004 | 0.10x | CN¥35.51 Million | CN¥359.36 Million | ▲ +20.3% |
| 2003 | 0.08x | CN¥23.79 Million | CN¥289.65 Million | ▼ -66.8% |
| 2002 | 0.25x | CN¥69.41 Million | CN¥281.00 Million | ▲ +1048.4% |
| 2001 | 0.02x | CN¥3.41 Million | CN¥158.59 Million | ▼ -37.6% |
| 2000 | 0.03x | CN¥3.66 Million | CN¥106.33 Million | ▼ -19.1% |
| 1999 | 0.04x | CN¥4.81 Million | CN¥112.94 Million | — |